About the Seminar

Present day cancer therapies suffer from severe primary or secondary side effects on normal tissue and resistance offered by cancer cells. Inhibition of checkpoint kinase 2 (ChK2) and 26s proteasome has the potential to improve these therapies by radioprotecting normal cells and sensitising the cancer cells. This talk will present the structure activity relationship studies of debromohymenialdisine to prepare better inhibitor of ChK2 and the concise synthesis of photoaffinity labelled imidazoline to determine the site of interaction of these non-competitive inhibitors with the proteasome. The last part of the talk will briefly describe the development [3+2]-cycloaddition reaction to obtain 1,2,4-triazoline and 1,2,4-triazole compounds.

Upcoming Seminars

17 April   | Aamir Rashid, Electrical Engineering

24 April   | Arif Zaman, Computer Science & Mathematics